Drug-resistant tuberculosis in Yangon, Myanmar
- PMID: 16308219
- DOI: 10.1080/00365540500265065
Drug-resistant tuberculosis in Yangon, Myanmar
Abstract
The extent of drug resistant tuberculosis (TB) in the capital city of Myanmar, Yangon has not yet been reported. This study aimed to determine the proportion and pattern of drug resistance to first-line anti-TB drugs, among Mycobacterium tuberculosis complex isolates from sputum smear positive TB patients who attended National TB Programme Yangon centres in April-August and October-December 2002. Drug susceptibility was determined by the Mycobacteria Growth Indicator Tube manual system (Becton Dickinson, MD, USA). Of the 567 patients, sputum specimens from 447 (79%) had a positive culture. Of these, 357 isolates (80%) had a susceptibility test result. Isolates from 76 of 259 (29.3%) new patients and from 45 of 98 (45.9%) previously treated patients were resistant to at least 1 of the anti-TB drugs. Resistance to isoniazid (INH) (22.0% vs 40.8%: new vs previously treated patients) and to > or =2 drugs (17.8% vs 29.6%: new vs previously treated patients) was common. Multidrug- resistant TB (MDR-TB) among new and previously treated patients was 4.2% and 18.4%, respectively. INH-resistant (adjusted OR: 2.0, 95% CI 1.1-3.6) and MDR-TB (adjusted OR: 3.4, 95% CI 1.4-8.3) cases were more likely to have taken anti-TB drugs > or =1 month previously. Collectively, prevalence of MDR-TB and TB resistance to > or =2 drugs are not rare in Yangon.
Similar articles
-
National anti-tuberculosis drug resistance survey, 2002, in Myanmar.Int J Tuberc Lung Dis. 2006 Oct;10(10):1111-6. Int J Tuberc Lung Dis. 2006. PMID: 17044203
-
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60. Int J Tuberc Lung Dis. 2009. PMID: 19723407
-
Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital.Ethiop Med J. 2008 Jul;46(3):219-25. Ethiop Med J. 2008. PMID: 19271385
-
Drug-resistant tuberculosis: past, present, future.Respirology. 2010 Apr;15(3):413-32. doi: 10.1111/j.1440-1843.2010.01738.x. Epub 2010 Mar 19. Respirology. 2010. PMID: 20337989 Review.
-
Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation.Ethiop Med J. 2002 Jan;40(1):79-86. Ethiop Med J. 2002. PMID: 12240570 Review.
Cited by
-
Responding to AIDS, tuberculosis, malaria, and emerging infectious diseases in Burma: dilemmas of policy and practice.PLoS Med. 2006 Oct;3(10):e393. doi: 10.1371/journal.pmed.0030393. PLoS Med. 2006. PMID: 17032061 Free PMC article. Review.
-
IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence.Public Health Action. 2018 Mar 21;8(1):20-24. doi: 10.5588/pha.17.0087. Public Health Action. 2018. PMID: 29581939 Free PMC article.
-
Genomic diversity among Beijing and non-Beijing Mycobacterium tuberculosis isolates from Myanmar.PLoS One. 2008 Apr 9;3(4):e1973. doi: 10.1371/journal.pone.0001973. PLoS One. 2008. PMID: 18398483 Free PMC article.
-
Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar.J Clin Microbiol. 2009 Feb;47(2):335-44. doi: 10.1128/JCM.01812-08. Epub 2008 Nov 26. J Clin Microbiol. 2009. PMID: 19036933 Free PMC article.
-
Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.Infect Dis Poverty. 2023 May 25;12(1):57. doi: 10.1186/s40249-023-01107-x. Infect Dis Poverty. 2023. PMID: 37231463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous